- cafead Jan 09, 2024 at 10:02: PM
via Novo Nordisk's (NOVOb.CO) CEO said on Tuesday he expects patients will stick with the company's popular obesity drug Wegovy for far longer than those using older treatments.
"We know from all medical interventions, stay time is not like a 100%... but I think we will see a significantly higher stay time than what we have seen so far on obesity treatment," said Lars Fruergaard Jorgensen at the JPMorgan Healthcare conference in San Francisco.
article source
"We know from all medical interventions, stay time is not like a 100%... but I think we will see a significantly higher stay time than what we have seen so far on obesity treatment," said Lars Fruergaard Jorgensen at the JPMorgan Healthcare conference in San Francisco.
article source